PharVision Advisers’s Astrana Health ASTH Stock Holding History

PharVision Advisers’s Portfolio ASTH Stock Details ASTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,695	Closed	-$211K	–	540
2024 Q4	$211K	Buy	+6,695	New	+$318K	0.18%	278

Other funds holding ASTH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PharVision Advisers's ASTH Position: Q1 2025 in Review

PharVision Advisers sold out of Astrana Health (ASTH) in Q1 2025, closing a stake of 6,695 shares — an estimated $211K sold.

PharVision Advisers first reported a position in ASTH in Q4 2024 and held it in 1 quarter. The position peaked at $211K in Q4 2024. 168 funds tracked by Wall St. Rank hold ASTH as of Q1 2025.

PharVision Advisers reported no remaining Astrana Health position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 6,695 Astrana Health shares in Q1 2025, an estimated $211K.
PharVision Advisers first reported a position in Astrana Health in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Astrana Health position peaked at $211K in Q4 2024.
168 funds tracked by Wall St. Rank held Astrana Health as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.